Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Phase 3, Placebo-Controlled, ASPIRE Study (TRC114968) of Eltrombopag (EPAG) Treatment of Thrombocytopenia (TCP) in Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Assessment of Clinical Benefit, Safety, and Tolerability

Moshe Mittelman, MD, Uwe Platzbecker, MD, Boris V Afanasyev, Professor, Sebastian Grosicki, MD PhD, Raymond SM Wong, MD, Achilles Anagnostopoulos, MD, Benjamin Brenner, MD, Claudio Denzlinger, MD, Giuseppe Rossi, MD, Arnon Nagler, MD MSc, Ana Isabel Rosell Mas, PhD, Frank Mannino, PhD, Nicole L. Stone, PhD, Geoffrey Chan, MD, Yasser Mostafa Kamel, MD MSc, MBA, Dominik L.D. Selleslag, MD

Blood (2015) 126 (23): 1661.

https://doi.org/10.1182/blood.V126.23.1661.1661

Published: 2015

Journal Articles

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

Dominik L.D. Selleslag, MD, Stefan Suciu, Giovanna Meloni, MD, Petra Muus, MD PhD, Constantijn J.M. Halkes, MD PhD, Adriano Venditti, MD, Safaa M Ramadan, MD PhD, Hans Pruijt, MD PhD, Liv Meert, MSc, Marco Vignetti, MD, Jean-Pierre Marie, MD, Dominique Bron, MD PhD, Theo de Witte, MD, Sergio Amadori, MD, Roelof Willemze, MD PhD, Frederic Baron, MD PhD

Blood (2014) 124 (21): 3675.

https://doi.org/10.1182/blood.V124.21.3675.3675

Published: 2014

Journal Articles

Selective Photodepletion of Recipient-Alloreactive T-Cells Enables Safe and Efficacious Haploidentical HSCT: Initial Results from a Phase 2 Trial in Patients with AML, ALL, and MDS

Denis-Claude Roy, MD, Johan Maertens, MD PhD, Irwin Walker, MBBS, Silvy Lachance, MD, Jean Roy, MD, Stephen Ronan Foley, MD, Philippe Lewalle, MD PhD, Dominik L.D. Selleslag, MD, Liesbeth De Jong, PhD, Jurjen H.L. Velthuis, PhD, Lisya Gerez, PhD, Karen Reitsma, PhD, Edwin Wagena, PhD, Stephan Mielke, MD

Blood (2014) 124 (21): 314.

https://doi.org/10.1182/blood.V124.21.314.314

Published: 2014

Journal Articles

Investigating Preferences and Factors Associated with Involvement In Treatment Decision-Making In Newly Diagnosed Patients with High-Risk Myelodysplastic Syndromes: An International Multicenter Study

Fabio Efficace, PhD, Gianluca Gaidano, MD, Maria Teresa Voso, MD, Giovanni Caocci, MD, Massimo Breccia, MD, Anna Angela Di Tucci, MD, Reinhard Stauder, MD, Dominik L.D. Selleslag, MD, Susan Wood, PhD, Chonghua Wan, MD, Grazia Sanpaolo, MD, Monia Lunghi, MD, Lodovico Balducci, MD, Francesco Cottone, PhD, Marco Vignetti, MD, Franco Mandelli, MD

Blood (2010) 116 (21): 4953.

https://doi.org/10.1182/blood.V116.21.4953.4953

Published: 2010

Journal Articles

Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.

David J Kuter, MD, DPhil, Mathias J Rummel, MD, PhD, Ralph Vincent Boccia, MD, B. Gail Macik, MD, Ingrid Pabinger, Dominik L.D. Selleslag, MD, Francesco Rodeghiero, Beng H Chong, MBBS, PhD, H. Müller-Beiβenhirtz, Lara Gehl, Xuena Wang, Dietmar Berger, MD, PhD

Blood (2009) 114 (22): 679.

https://doi.org/10.1182/blood.V114.22.679.679

Published: 2009

Journal Articles

Value of Low Dose IL-2 as Maintenance Following Consolidation Treatment or Autologous Transplantation in Acute Myelogenous Leukemia (AML) Patients Aged 15-60 Years Who Reached CR After High Dose (HD-AraC) Vs Standard Dose (SD-AraC) Cytosine Arabinoside During Induction: Results of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups.

Blood (2009) 114 (22): 791.

https://doi.org/10.1182/blood.V114.22.791.791

Published: 2009

Journal Articles

High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SDAraC) during Induction and Value of IL-2 during Maintenance in Acute Myelogenous Leukemia (AML): Impact of AraC Dose on Complete Remission Rate and Toxicity (Results on the first 1700 randomized patients of the AML-12 trial of EORTC and GIMEMA Leukemia Groups)

Blood (2008) 112 (11): 134.

https://doi.org/10.1182/blood.V112.11.134.134

Published: 2008

Journal Articles

MicroRNA signatures in Genetic Subtypes of T-Cell Acute Lymphoblastic Leukemia.

Blood (2008) 112 (11): 3360.

https://doi.org/10.1182/blood.V112.11.3360.3360

Published: 2008

Journal Articles

Results of Haploidentical Stem Cell Transplantation after a Conditioning Regimen without Total Body Irradiation in Elderly Patients with Advanced Myeloid and Lymphoid Malignancies.

Dominik L.D. Selleslag, MD, Melanny Hidajat, M.D., Jan Van Droogenbroeck, M.D., Achiel Van Hoof, M.D., Johan Billiet, M.D, Dimitri Dehenau, Ph., Friedel Nollet, Ph.D., Arnold Criel, M.D., Ph.D.

Blood (2007) 110 (11): 3074.

https://doi.org/10.1182/blood.V110.11.3074.3074

Published: 2007

Journal Articles

Assessment of Two Doses of Infliximab in Patients with Low/Intermediate Risk IPSS Myelodysplastic Syndrome (MDS): An EORTC Leukemia Group (LG) Randomized Phase II Trial (06023).

Liliana Baila, Stefan Suciu, Petra Muus, Sergio Amadori, Michel Delforge, Gert Ossenkoppele, Dominik L.D. Selleslag, Antoine Thyss, Hilde Demuynk, Alain Gadisseur, P. Vermeulen, Carla De Boer, Heinz Zwierzina, T.M. de Witte

Blood (2007) 110 (11): 1456.

https://doi.org/10.1182/blood.V110.11.1456.1456

Published: 2007

Journal Articles

Efficacy of Donor Lymphocyte Infusions in Myelodysplastic Syndromes Relapsing after Allogeneic Stem Cell Transplantation: Importance of Karyotype.

Dominik L.D. Selleslag, M.D., Friedel Nollet, Ph.D., Johan Billiet, M.D., Jan Van Droogenbroeck, M.D., Achiel Van Hoof, M.D., Koen Van Eygen, M.D., Melanny Hidajat, M.D., Arnold Criel, M.D.

Blood (2004) 104 (11): 1450.

https://doi.org/10.1182/blood.V104.11.1450.1450

Published: 2004

NARROW

Phase 3, Placebo-Controlled, ASPIRE Study (TRC114968) of Eltrombopag (EPAG) Treatment of Thrombocytopenia (TCP) in Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Assessment of Clinical Benefit, Safety, and Tolerability

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

Selective Photodepletion of Recipient-Alloreactive T-Cells Enables Safe and Efficacious Haploidentical HSCT: Initial Results from a Phase 2 Trial in Patients with AML, ALL, and MDS

Investigating Preferences and Factors Associated with Involvement In Treatment Decision-Making In Newly Diagnosed Patients with High-Risk Myelodysplastic Syndromes: An International Multicenter Study

Comparison of Splenectomy and Treatment Failure Incidence in Nonsplenectomized Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim or Medical Standard of Care: 1-Year Treatment and 6-Month Safety Follow-up.

MicroRNA signatures in Genetic Subtypes of T-Cell Acute Lymphoblastic Leukemia.

Results of Haploidentical Stem Cell Transplantation after a Conditioning Regimen without Total Body Irradiation in Elderly Patients with Advanced Myeloid and Lymphoid Malignancies.

Assessment of Two Doses of Infliximab in Patients with Low/Intermediate Risk IPSS Myelodysplastic Syndrome (MDS): An EORTC Leukemia Group (LG) Randomized Phase II Trial (06023).

Efficacy of Donor Lymphocyte Infusions in Myelodysplastic Syndromes Relapsing after Allogeneic Stem Cell Transplantation: Importance of Karyotype.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only